NCT00239239View on ClinicalTrials.gov

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

March 31, 2007

Conditions

Non-Myeloid MalignanciesAnemiaCancer

Interventions

DRUG

Darbepoetin alfa

darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY